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Background: Several studies tested intravenous (IV) bolus and continuous administration of pressors during percutaneous coronary intervention 
(PCI). However, no data is available considering giving neosynephrine as intracoronary (IC) bolus during PCI.
Objectives: This study evaluated the immediate and intermediate results of IC neosynephrine administration during PCI.
Methods: Clinical outcomes of 940 patients who received coronary stent(s) + pressors by three applications for hemodynamic support during PCI 
and were followed up for over 36 months. Group A (345 patients) had IC neosynephrine bolus only; group B (297 patients) had IV neosynephrine 
bolus ± IV infusion and group C (298 patients) had IV epinephrine bolus ± infusion. The standard periprocedure administration of aspirin, 
clopidogrel, heparin and GP IIb, IIIa inhibitors were similar among all groups.
Results: There were 640 males (68%), mean age 56 ± 12. Among them 51% were diabetics. The immediate improvement in hemodynamic, TIMI 
flow, electrocardiogram and chest pain was higher in group A compared to group B (OR 2.6, p= 0.039) and group C (OR 3.4, p= 0.031), no coronary 
spasm were noted in all groups. The 6, 12, 36-month cumulative composite endpoint of death and myocardial infraction (MI) was lower in group A 
(2.9%) compared to group C (5.1%, OR 3.3, p= 0.033), and group-B (4.0%, OR 2.6, p = 0.044). Compared to group-A, target vessel revascularization 
(TVR) was two fold in group-C (OR 2.3, p = 0.038) and similar in group-B (OR 1.4, p = 0.061). Bleeding was similar among all groups (p= 0.29). 
Hospital stay was significantly lower in group A (1.5 ± 0.4 day) compared to group B (2.1 ± 0.5 day) and group C (2.5 ± 0.7 day) (P =0.009). Table
Conclusions: The IC bolus alone application of neosynephrine may be safer and superior to the IV administration of neosynephrine or epinephrine 
during PCI. Large-scale prospective randomized trials are needed to further validate these findings.
